Table 1.
Loco-regional control and survival by type of analyses and other main factors.
| Anatomical site | Stage | Treatment intention | Significant-NSe/no. of total reports [references] | LRCa [references] |
SVb [references] |
Comments [references] | ||
|---|---|---|---|---|---|---|---|---|
| Mv-Anc | Un-And | Mv-Anc | Un-And | |||||
| Larynx | I–II | Radical | Significant: 9/12 [10–18] NS: 3/12 [19–21] |
Significant: 7/9 [10–14,16,18] NS: 2/9 [20,21] |
Significant: 2/3 [15,17] NS: 1/3 [19] |
Significant: 2/3 [14,16] NS: 1/3 [21] |
NS: 1/1 [19] | LRCa, p = 0.08 for stage I [19] Not significant for OSf or DFSg [21] |
| III–IV | Radical | Significant: 1/1 [7] | Significant: 1/1 [7] | |||||
| Mixed stages | Radical | Significant: 12/13 [22–33] NS: 1/13 [34] |
Significant: 7/8 [22,23,27–30,32] NS: 1/8 [34] |
Significant: 5/5 [24–26,31,33] | Significant: 1/1 [28] | Significant: 1/1 [24] | Larynx and hypopharynx ± larynx. Included here for majority of larynx patients [23] LRCa, p = 0.08 [34] |
|
| Total larynx | Significant: 22/26 (84.6%) | Significant: 14/17 (82.3%) | Significant: 8/9 (88.9%) | Significant: 3/4 (75%) | Significant: 1/2 (50%) | Total Significant LRCa: 22/26 (84.6%) Total Significant SVb: 4/6 (66.7%) |
||
| Mixed location | III–IV | Radical | Significant: 3/3 [35–37] | Significant: 2/2 [35,37] | Significant: 1/1 [36] | NS: 1/1 [36] | Hyperfractionation and Accelerat. Concom. boost fractionat. arms: trend toward improved DFSg (p = 0.067 and p = 0.054, respect.). OSf NSe [36] | |
| Adjuvant | Significant: 1/2 [38] NS: 1/2 [39] |
Significant: 1/1 [38] | NS: 1/1 [39] | NS: 1/1 [38] | NS: 1/1 [39] | Tpot showed correlation with DFSg (↓ 14%), but not in MV-Anc [38] High-risk patients, Acceler. Fraction. trends for > LRCa (p = 0.11) and for > OSf (p = 0.08) [39] |
||
| Mixed stages | Radical | Significant: 13/13 [8,9,40–50] | Significant: 5/5 [43,44,47,48,50] | Significant: 7/7 [8,9,40–42,45,49] | Significant: 4/5 [43,44,46,50] NS: 1/6 [48] |
Significant: 1/1 [40] | LRCa Significant in Ni+ (p = 0.07–0.08 in Tj3-4). OSf Significant in Stage III-IV [40] LRCa Significant in advan. stages. CSSh, p = 0.06 [48] Significant for LRCa (any T, not Ni), preservation of voice and CSSh. OSf not improved [50] |
|
| Adjuvant | Significant: 2/3 [51,52] NS: 1/3 [53] |
Significant: 2/2 [51,52] | NS: 1/1 [53] | Significant: 1/1 [51] | ||||
| Mixed | Significant: 2/2 [54,55] | Significant: 1/1 [55] | Significant: 1/1 [54] | SEER–Medicare linked database. OSf Significant for laryngeal cancer, trend for salivary gland (p = 0.06). Remaining locations not significant, ‘attributable to smaller sample sizes’ [55] | ||||
| Total mixed location | Significant: 21/23 (91.3%) | Significant: 10/10 (100%) | Significant: 8/10 (80%) | Significant: 6/8 (75%) | Significant: 2/4 (50%) | Total Significant LRCa: 18/20 (90%) Total Significant SVb: 8/12 (66.7%) |
||
| Naso-pharynx | Mixed stages | Radical | Significant: 2/3 (66.6%) [56,57] NS: 1/3 [58] |
Significant: 1/2 (50%) [57] NS: 1/2 [58] |
Significant: 1/1 (100%) [56] | Significant: 1/1 (100%) [57] | Nodal control, p = 0.06 [58] | |
| Oro-pharynx | Mixed stages | Radical | Significant: 7/7 (100%) [59–65] | Significant: 6/6 (100%) [60–65] | Significant: 1/1 (100%) [59] | Significant: 1/1 (100%) [65] | Significant: 1/1 (100%) [63] | |
| Oral cavity | I–II | Radical | Significant: 1/1 (100%) [66] | Significant: 1/1 (100%) [66] | ||||
| Mixed stages | Adjuvant | NS: 1/1 (100%) [67] | NS: 1/1 (100%) [67] | LRCa for OTTk <52 days (R0k, p = 0.11), < 46 days (R1l, p = 0.18) [67] | ||||
| Total | Significant: 53/61 (86.9%) | Significant: 31/35 (88.6%) | Significant: 19/23 (82.6%) | Significant: 11/14 (78.6%) | Significant: 4/7 (57.1%) | Total Significant LRCa: 50/58 (86.2%) Total Significant SVb: 15/21 (71.4%)* |
||
| Total without AFx | Significant: 48/54 (88.9%) | Significant: 28/31 (90.3%) | Significant: 18/21 (85.7%) | Significant: 10/10 (100%) | Significant: 4/5 (80%) | Total Significant LRCa: 47/53 (88.7%) Total Significant SVb: 14/15 (93.3%)* |
||
a
LCR, loco-regional control.
b
SV, survival (any kind, see Section 2).
c
Mv-An, multivariate analysis.
d
Un-An, univariate analysis.
e
NS, not significant.
f
OS, overall survival.
g
DFS, disease-free survival.
h
CSS, cancer-specific survival.
i
N, N-stage.
j
T, T-stage.
k
OTT, overall treatment time. kR0, complete surgical resection.
l
R1, incomplete surgical resection (microscopic disease).
*
Mostly referred to OS.